Picture of Biomerica logo

BMRA — Biomerica News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapNeutral

Biomerica Inc expected to post a loss of 8  cents a share - Earnings Preview

* Biomerica Inc  BMRA.OQ   BMRA.O  is expected to show a fall in
quarterly revenue when it reports results on May 6 (estimated).
* The Irvine, California-based company is expected to report   a
3.3% decrease in revenue to $2.634 million from $2.73 million a
year ago, according to the mean estimate from 3 analysts, based
on Refinitiv data.
​* Refinitiv's mean analyst estimate for Biomerica Inc is for a
loss of 8 cents per share. For the same quarter last year, the
company reported a loss of 4 cents per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts had fallen by
about 4.3% in the last three months. ​
* Wall Street's median 12-month price target for Biomerica Inc
is $10.5​, about 57.8% above​ its last closing price
of $4.43. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Feb. 28 2021  -0.03       -0.08      -0.15     Missed  -87.5
 Nov. 30 2020  -0.10       -0.10      -0.13     Missed  -33.3
 Aug. 31 2020  -0.08       -0.08      -0.14     Missed  -75​
 May. 31 2020  -0.07       -0.07      -0.04     Beat    40
 Feb.          -0.07​      -0.06      -0.09     Missed  -38.5​
 29​ 2020​                                              
 Nov. 30 2019              -0.08      -0.05     Beat    37.5​
 Aug. 31 2019  -0.06       -0.06      -0.05     Beat    16.7
 May. 31 2019              -0.08      -0.08     Met     0
 This summary was machine generated May 4 at 22:52 GMT.  All
figures in US dollars unless otherwise stated

Recent news on Biomerica

See all news